<DOC>
	<DOCNO>NCT01373632</DOCNO>
	<brief_summary>Sirolimus-eluting stent ( SES ) world-widely used clinical practice treat patient coronary artery disease ( CAD ) . The efficacy safety Excel SES ( JW Medical , Shandong , China , MA ) biodegradable polymer prove several clinical trial . Here investigator design prospective , multicenter , randomize clinical study purpose identify non-inferiority efficacy safety treat CAD patient Firebird 2 SES ( Microport , Shanghai ) durable polymer , compare Excel SES .</brief_summary>
	<brief_title>Firebird 2 Versus Excel Sirolimus-eluting Stent Treating Real-world Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>age &gt; 18 year male unpregnant female stenosis &gt; 70 % one major epicardial coronary artery contraindication stent implantation sing informed consent acute myocardial infarction within one week contraindication stent implantation tolerate dual antiplatelet therapy history stent implantation within last oneyear receive brand coronary stent index procedure achievement inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>significant stenosis ( &gt; 70 % lumen stenosis )</keyword>
	<keyword>epicardial coronary artery</keyword>
	<keyword>clinical ischemic</keyword>
</DOC>